#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Protocols to Induce Mature EC Phenotype
2-1	4-13	Protocols	abstract	new	coref	5-16[23_0]
2-2	14-16	to	_	_	_	_
2-3	17-23	Induce	_	_	_	_
2-4	24-30	Mature	abstract[4]	new[4]	ana	3-1[0_4]
2-5	31-33	EC	organization|abstract[4]	new|new[4]	coref	17-10
2-6	34-43	Phenotype	abstract[4]	new[4]	_	_

#Text=It is well known that for clinical use , it is mandatory to generate cells able to show a high degree of commitment .
3-1	44-46	It	abstract	giv	_	_
3-2	47-49	is	_	_	_	_
3-3	50-54	well	_	_	_	_
3-4	55-60	known	_	_	_	_
3-5	61-65	that	_	_	_	_
3-6	66-69	for	_	_	_	_
3-7	70-78	clinical	abstract[6]	new[6]	_	_
3-8	79-82	use	abstract[6]	new[6]	_	_
3-9	83-84	,	_	_	_	_
3-10	85-87	it	abstract	new	cata	3-10[0_8]
3-11	88-90	is	_	_	_	_
3-12	91-100	mandatory	_	_	_	_
3-13	101-103	to	abstract[8]	new[8]	_	_
3-14	104-112	generate	abstract[8]	new[8]	_	_
3-15	113-118	cells	abstract[8]|object	new[8]|new	ana	5-20
3-16	119-123	able	abstract[8]	new[8]	_	_
3-17	124-126	to	abstract[8]	new[8]	_	_
3-18	127-131	show	abstract[8]	new[8]	_	_
3-19	132-133	a	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-20	134-138	high	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-21	139-145	degree	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-22	146-148	of	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-23	149-159	commitment	abstract[8]|abstract[10]|abstract	new[8]|new[10]|new	_	_
3-24	160-161	.	_	_	_	_

#Text=This requirement fulfills not only functional issues , but also safety ones , in order to prevent teratoma formation after implantation .
4-1	162-166	This	abstract[12]	new[12]	_	_
4-2	167-178	requirement	abstract[12]	new[12]	_	_
4-3	179-187	fulfills	_	_	_	_
4-4	188-191	not	_	_	_	_
4-5	192-196	only	abstract[13]	new[13]	_	_
4-6	197-207	functional	abstract[13]	new[13]	_	_
4-7	208-214	issues	abstract[13]	new[13]	_	_
4-8	215-216	,	_	_	_	_
4-9	217-220	but	_	_	_	_
4-10	221-225	also	_	_	_	_
4-11	226-232	safety	abstract|object[15]	new|new[15]	coref|coref	28-9[186_15]|28-9[186_15]
4-12	233-237	ones	object[15]	new[15]	_	_
4-13	238-239	,	_	_	_	_
4-14	240-242	in	_	_	_	_
4-15	243-248	order	_	_	_	_
4-16	249-251	to	_	_	_	_
4-17	252-259	prevent	_	_	_	_
4-18	260-268	teratoma	abstract|event[17]	new|new[17]	_	_
4-19	269-278	formation	event[17]	new[17]	_	_
4-20	279-284	after	event[17]	new[17]	_	_
4-21	285-297	implantation	event[17]|event	new[17]|new	_	_
4-22	298-299	.	_	_	_	_

#Text=Thus , a prerequisite to exploit iPSC-ECs in the clinical setting is the development of defined protocols to guide their differentiation into functional endothelial cells .
5-1	300-304	Thus	_	_	_	_
5-2	305-306	,	_	_	_	_
5-3	307-308	a	abstract[19]	new[19]	coref	5-13[22_19]
5-4	309-321	prerequisite	abstract[19]	new[19]	_	_
5-5	322-324	to	_	_	_	_
5-6	325-332	exploit	_	_	_	_
5-7	333-341	iPSC-ECs	object	new	_	_
5-8	342-344	in	_	_	_	_
5-9	345-348	the	time[21]	new[21]	_	_
5-10	349-357	clinical	time[21]	new[21]	_	_
5-11	358-365	setting	time[21]	new[21]	_	_
5-12	366-368	is	_	_	_	_
5-13	369-372	the	abstract[22]	giv[22]	coref	19-8[121_22]
5-14	373-384	development	abstract[22]	giv[22]	_	_
5-15	385-387	of	abstract[22]	giv[22]	_	_
5-16	388-395	defined	abstract[22]|abstract[23]	giv[22]|giv[23]	coref	17-4[95_23]
5-17	396-405	protocols	abstract[22]|abstract[23]	giv[22]|giv[23]	_	_
5-18	406-408	to	_	_	_	_
5-19	409-414	guide	_	_	_	_
5-20	415-420	their	object|event[25]	giv|new[25]	coref|coref|coref|coref	5-23[27_0]|7-12[38_25]|5-23[27_0]|7-12[38_25]
5-21	421-436	differentiation	event[25]	new[25]	_	_
5-22	437-441	into	_	_	_	_
5-23	442-452	functional	object[27]	giv[27]	coref	6-24[31_27]
5-24	453-464	endothelial	object|object[27]	new|giv[27]	_	_
5-25	465-470	cells	object[27]	giv[27]	_	_
5-26	471-472	.	_	_	_	_

#Text=The ideal induction protocol should be reproducible , easy to perform and relatively quick in order to allow yielding an adequate quantity of homogeneous cells .
6-1	473-476	The	abstract[29]	new[29]	coref	25-4[166_29]
6-2	477-482	ideal	abstract[29]	new[29]	_	_
6-3	483-492	induction	abstract|abstract[29]	new|new[29]	coref	7-2
6-4	493-501	protocol	abstract[29]	new[29]	_	_
6-5	502-508	should	_	_	_	_
6-6	509-511	be	_	_	_	_
6-7	512-524	reproducible	_	_	_	_
6-8	525-526	,	_	_	_	_
6-9	527-531	easy	_	_	_	_
6-10	532-534	to	_	_	_	_
6-11	535-542	perform	_	_	_	_
6-12	543-546	and	_	_	_	_
6-13	547-557	relatively	_	_	_	_
6-14	558-563	quick	_	_	_	_
6-15	564-566	in	_	_	_	_
6-16	567-572	order	_	_	_	_
6-17	573-575	to	_	_	_	_
6-18	576-581	allow	_	_	_	_
6-19	582-590	yielding	_	_	_	_
6-20	591-593	an	quantity[30]	new[30]	_	_
6-21	594-602	adequate	quantity[30]	new[30]	_	_
6-22	603-611	quantity	quantity[30]	new[30]	_	_
6-23	612-614	of	quantity[30]	new[30]	_	_
6-24	615-626	homogeneous	quantity[30]|object[31]	new[30]|giv[31]	coref	7-18[41_31]
6-25	627-632	cells	quantity[30]|object[31]	new[30]|giv[31]	_	_
6-26	633-634	.	_	_	_	_

#Text=Current induction strategies include embryonic bodies ( EB ) generation , differentiation on monolayers and co-culture with primary cells (
7-1	635-642	Current	abstract[33]	new[33]	_	_
7-2	643-652	induction	abstract|abstract[33]	giv|new[33]	coref	15-8[84_0]
7-3	653-663	strategies	abstract[33]	new[33]	_	_
7-4	664-671	include	_	_	_	_
7-5	672-681	embryonic	object[34]	new[34]	appos	7-7[37_34]
7-6	682-688	bodies	object[34]	new[34]	_	_
7-7	689-690	(	person[36]|object[37]	new[36]|giv[37]	_	_
7-8	691-693	EB	object|person[36]|object[37]	new|new[36]|giv[37]	coref	10-12
7-9	694-695	)	person[36]|object[37]	new[36]|giv[37]	_	_
7-10	696-706	generation	person[36]|object[37]	new[36]|giv[37]	_	_
7-11	707-708	,	object[37]	giv[37]	_	_
7-12	709-724	differentiation	object[37]|event[38]	giv[37]|giv[38]	coref	12-21[0_38]
7-13	725-727	on	object[37]|event[38]	giv[37]|giv[38]	_	_
7-14	728-738	monolayers	object[37]|event[38]|object	giv[37]|giv[38]|new	_	_
7-15	739-742	and	object[37]|event[38]	giv[37]|giv[38]	_	_
7-16	743-753	co-culture	object[37]|event[38]|abstract[40]	giv[37]|giv[38]|new[40]	coref	13-4[67_40]
7-17	754-758	with	object[37]|event[38]|abstract[40]	giv[37]|giv[38]|new[40]	_	_
7-18	759-766	primary	object[37]|event[38]|abstract[40]|object[41]	giv[37]|giv[38]|new[40]|giv[41]	coref	11-21[55_41]
7-19	767-772	cells	object[37]|event[38]|abstract[40]|object[41]	giv[37]|giv[38]|new[40]|giv[41]	_	_
7-20	773-774	(	_	_	_	_

#Text=Figure 4
8-1	775-781	Figure	abstract[42]	new[42]	_	_
8-2	782-783	4	abstract[42]	new[42]	_	_

#Text=) .
9-1	784-785	)	_	_	_	_
9-2	786-787	.	_	_	_	_

#Text=IPSCs tend to self-assemble into three-dimensional ( 3D ) structures ( EB ) when grown in suspension .
10-1	788-793	IPSCs	object	new	_	_
10-2	794-798	tend	_	_	_	_
10-3	799-801	to	_	_	_	_
10-4	802-815	self-assemble	_	_	_	_
10-5	816-820	into	_	_	_	_
10-6	821-838	three-dimensional	abstract[45]	new[45]	coref	11-26[56_45]
10-7	839-840	(	abstract[45]	new[45]	_	_
10-8	841-843	3D	abstract|abstract[45]	new|new[45]	_	_
10-9	844-845	)	abstract[45]	new[45]	_	_
10-10	846-856	structures	abstract[45]	new[45]	_	_
10-11	857-858	(	_	_	_	_
10-12	859-861	EB	place	giv	coref	11-21
10-13	862-863	)	_	_	_	_
10-14	864-868	when	_	_	_	_
10-15	869-874	grown	_	_	_	_
10-16	875-877	in	_	_	_	_
10-17	878-888	suspension	substance	new	_	_
10-18	889-890	.	_	_	_	_

#Text=From EBs , cell aggregates encompassing all three germ layers develop , and afterwards , within the positive mesodermal , EB cells tend to form vascular structures .
11-1	891-895	From	_	_	_	_
11-2	896-899	EBs	object	new	_	_
11-3	900-901	,	_	_	_	_
11-4	902-906	cell	place|abstract[50]	new|new[50]	coref|coref	13-8|13-8
11-5	907-917	aggregates	abstract[50]	new[50]	_	_
11-6	918-930	encompassing	_	_	_	_
11-7	931-934	all	abstract[52]	new[52]	_	_
11-8	935-940	three	abstract[52]	new[52]	_	_
11-9	941-945	germ	substance|abstract[52]	new|new[52]	_	_
11-10	946-952	layers	abstract[52]	new[52]	_	_
11-11	953-960	develop	_	_	_	_
11-12	961-962	,	_	_	_	_
11-13	963-966	and	_	_	_	_
11-14	967-977	afterwards	_	_	_	_
11-15	978-979	,	_	_	_	_
11-16	980-986	within	_	_	_	_
11-17	987-990	the	object[53]	new[53]	coref	24-6[0_53]
11-18	991-999	positive	object[53]	new[53]	_	_
11-19	1000-1010	mesodermal	object[53]	new[53]	_	_
11-20	1011-1012	,	_	_	_	_
11-21	1013-1015	EB	substance|object[55]	giv|giv[55]	coref|coref	15-5[83_55]|15-5[83_55]
11-22	1016-1021	cells	object[55]	giv[55]	_	_
11-23	1022-1026	tend	_	_	_	_
11-24	1027-1029	to	_	_	_	_
11-25	1030-1034	form	_	_	_	_
11-26	1035-1043	vascular	abstract[56]	giv[56]	_	_
11-27	1044-1054	structures	abstract[56]	giv[56]	_	_
11-28	1055-1056	.	_	_	_	_

#Text=This method is affected by low efficiency ( 1 – 5 % ) and slow production rate ; however , differentiation can be improved by adding proper growth factors to the culture medium .
12-1	1057-1061	This	abstract[57]	new[57]	_	_
12-2	1062-1068	method	abstract[57]	new[57]	_	_
12-3	1069-1071	is	_	_	_	_
12-4	1072-1080	affected	_	_	_	_
12-5	1081-1083	by	_	_	_	_
12-6	1084-1087	low	abstract[58]	new[58]	_	_
12-7	1088-1098	efficiency	abstract[58]	new[58]	_	_
12-8	1099-1100	(	_	_	_	_
12-9	1101-1102	1	quantity[59]	new[59]	coref	22-25[0_59]
12-10	1103-1104	–	quantity[59]	new[59]	_	_
12-11	1105-1106	5	quantity[59]	new[59]	_	_
12-12	1107-1108	%	quantity[59]	new[59]	_	_
12-13	1109-1110	)	_	_	_	_
12-14	1111-1114	and	_	_	_	_
12-15	1115-1119	slow	abstract[61]	new[61]	_	_
12-16	1120-1130	production	abstract|abstract[61]	new|new[61]	coref	22-9[150_0]
12-17	1131-1135	rate	abstract[61]	new[61]	_	_
12-18	1136-1137	;	_	_	_	_
12-19	1138-1145	however	_	_	_	_
12-20	1146-1147	,	_	_	_	_
12-21	1148-1163	differentiation	event	giv	coref	13-13[71_0]
12-22	1164-1167	can	_	_	_	_
12-23	1168-1170	be	_	_	_	_
12-24	1171-1179	improved	_	_	_	_
12-25	1180-1182	by	_	_	_	_
12-26	1183-1189	adding	_	_	_	_
12-27	1190-1196	proper	abstract[64]	new[64]	coref	16-11[89_64]
12-28	1197-1203	growth	abstract|abstract[64]	new|new[64]	_	_
12-29	1204-1211	factors	abstract[64]	new[64]	_	_
12-30	1212-1214	to	abstract[64]	new[64]	_	_
12-31	1215-1218	the	abstract[64]|abstract[65]	new[64]|new[65]	coref	17-23[0_65]
12-32	1219-1226	culture	abstract[64]|abstract[65]	new[64]|new[65]	_	_
12-33	1227-1233	medium	abstract[64]|abstract[65]	new[64]|new[65]	_	_
12-34	1234-1235	.	_	_	_	_

#Text=Another approach involves a co-culture with primary cell lines able to induce iPSC-EC differentiation toward mature ECs .
13-1	1236-1243	Another	abstract[66]	new[66]	_	_
13-2	1244-1252	approach	abstract[66]	new[66]	_	_
13-3	1253-1261	involves	_	_	_	_
13-4	1262-1263	a	abstract[67]	giv[67]	_	_
13-5	1264-1274	co-culture	abstract[67]	giv[67]	_	_
13-6	1275-1279	with	abstract[67]	giv[67]	_	_
13-7	1280-1287	primary	abstract[67]|object[69]	giv[67]|new[69]	_	_
13-8	1288-1292	cell	abstract[67]|place|object[69]	giv[67]|giv|new[69]	coref	14-23
13-9	1293-1298	lines	abstract[67]|object[69]	giv[67]|new[69]	_	_
13-10	1299-1303	able	abstract[67]|object[69]	giv[67]|new[69]	_	_
13-11	1304-1306	to	abstract[67]|object[69]	giv[67]|new[69]	_	_
13-12	1307-1313	induce	abstract[67]|object[69]	giv[67]|new[69]	_	_
13-13	1314-1321	iPSC-EC	abstract[67]|object[69]|abstract|event[71]	giv[67]|new[69]|new|giv[71]	coref|coref	16-1[87_71]|16-1[87_71]
13-14	1322-1337	differentiation	abstract[67]|object[69]|event[71]	giv[67]|new[69]|giv[71]	_	_
13-15	1338-1344	toward	_	_	_	_
13-16	1345-1351	mature	object[72]	new[72]	coref	14-10[75_72]
13-17	1352-1355	ECs	object[72]	new[72]	_	_
13-18	1356-1357	.	_	_	_	_

#Text=In detail , Choi et al. directed hiPSCs into mature ECs in the presence of OP9 , a mouse bone marrow stromal cell line .
14-1	1358-1360	In	_	_	_	_
14-2	1361-1367	detail	_	_	_	_
14-3	1368-1369	,	_	_	_	_
14-4	1370-1374	Choi	person	new	_	_
14-5	1375-1377	et	_	_	_	_
14-6	1378-1381	al.	_	_	_	_
14-7	1382-1390	directed	_	_	_	_
14-8	1391-1397	hiPSCs	abstract	new	coref	17-19[99_0]
14-9	1398-1402	into	_	_	_	_
14-10	1403-1409	mature	object[75]	giv[75]	coref	18-25[119_75]
14-11	1410-1413	ECs	object[75]	giv[75]	_	_
14-12	1414-1416	in	_	_	_	_
14-13	1417-1420	the	abstract[76]	new[76]	_	_
14-14	1421-1429	presence	abstract[76]	new[76]	_	_
14-15	1430-1432	of	abstract[76]	new[76]	_	_
14-16	1433-1436	OP9	abstract[76]|object	new[76]|new	appos	14-18[81_0]
14-17	1437-1438	,	_	_	_	_
14-18	1439-1440	a	object[81]	giv[81]	_	_
14-19	1441-1446	mouse	object[81]	giv[81]	_	_
14-20	1447-1451	bone	object[81]	giv[81]	_	_
14-21	1452-1458	marrow	animal|object[81]	new|giv[81]	_	_
14-22	1459-1466	stromal	animal|object[81]	new|giv[81]	_	_
14-23	1467-1471	cell	object|object[81]	giv|giv[81]	coref	31-22
14-24	1472-1476	line	object[81]	giv[81]	_	_
14-25	1477-1478	.	_	_	_	_

#Text=The authors speculated that these cells regulate iPSC induction via a paracrine signaling .
15-1	1479-1482	The	person[82]	new[82]	ana	17-28[102_82]
15-2	1483-1490	authors	person[82]	new[82]	_	_
15-3	1491-1501	speculated	_	_	_	_
15-4	1502-1506	that	_	_	_	_
15-5	1507-1512	these	object[83]	giv[83]	coref	18-22[118_83]
15-6	1513-1518	cells	object[83]	giv[83]	_	_
15-7	1519-1527	regulate	_	_	_	_
15-8	1528-1532	iPSC	abstract[84]	giv[84]	coref	23-3[156_84]
15-9	1533-1542	induction	abstract[84]	giv[84]	_	_
15-10	1543-1546	via	_	_	_	_
15-11	1547-1548	a	abstract[85]	new[85]	coref	20-5[126_85]
15-12	1549-1558	paracrine	abstract[85]	new[85]	_	_
15-13	1559-1568	signaling	abstract[85]	new[85]	_	_
15-14	1569-1570	.	_	_	_	_

#Text=Monolayer differentiation holds a significantly higher efficiency that depends on external factors , such as medium constituents , showing a final yield that is still too low in the view of clinical applications .
16-1	1571-1580	Monolayer	person|event[87]	new|giv[87]	coref|coref	17-43[107_87]|17-43[107_87]
16-2	1581-1596	differentiation	event[87]	giv[87]	_	_
16-3	1597-1602	holds	_	_	_	_
16-4	1603-1604	a	abstract[88]	new[88]	coref	22-24[155_88]
16-5	1605-1618	significantly	abstract[88]	new[88]	_	_
16-6	1619-1625	higher	abstract[88]	new[88]	_	_
16-7	1626-1636	efficiency	abstract[88]	new[88]	_	_
16-8	1637-1641	that	_	_	_	_
16-9	1642-1649	depends	_	_	_	_
16-10	1650-1652	on	_	_	_	_
16-11	1653-1661	external	abstract[89]	giv[89]	coref	17-33[105_89]
16-12	1662-1669	factors	abstract[89]	giv[89]	_	_
16-13	1670-1671	,	abstract[89]	giv[89]	_	_
16-14	1672-1676	such	abstract[89]	giv[89]	_	_
16-15	1677-1679	as	abstract[89]	giv[89]	_	_
16-16	1680-1686	medium	abstract[89]|substance[90]	giv[89]|new[90]	_	_
16-17	1687-1699	constituents	abstract[89]|substance[90]	giv[89]|new[90]	_	_
16-18	1700-1701	,	_	_	_	_
16-19	1702-1709	showing	_	_	_	_
16-20	1710-1711	a	abstract[91]	new[91]	_	_
16-21	1712-1717	final	abstract[91]	new[91]	_	_
16-22	1718-1723	yield	abstract[91]	new[91]	_	_
16-23	1724-1728	that	_	_	_	_
16-24	1729-1731	is	_	_	_	_
16-25	1732-1737	still	_	_	_	_
16-26	1738-1741	too	_	_	_	_
16-27	1742-1745	low	_	_	_	_
16-28	1746-1748	in	_	_	_	_
16-29	1749-1752	the	abstract[92]	new[92]	coref	21-2[129_92]
16-30	1753-1757	view	abstract[92]	new[92]	_	_
16-31	1758-1760	of	abstract[92]	new[92]	_	_
16-32	1761-1769	clinical	abstract[92]|abstract[93]	new[92]|new[93]	_	_
16-33	1770-1782	applications	abstract[92]|abstract[93]	new[92]|new[93]	_	_
16-34	1783-1784	.	_	_	_	_

#Text=To date , the best protocols showing the highest EC yields were developed by culturing a monolayer of hiPSCs on a matrix-coated culture plate and by treating them with different molecules or growth factors in a timed fashion in order to guide the progressive differentiation of hiPSCs toward the EC lineage .
17-1	1785-1787	To	_	_	_	_
17-2	1788-1792	date	time	new	_	_
17-3	1793-1794	,	_	_	_	_
17-4	1795-1798	the	abstract[95]	giv[95]	_	_
17-5	1799-1803	best	abstract[95]	giv[95]	_	_
17-6	1804-1813	protocols	abstract[95]	giv[95]	_	_
17-7	1814-1821	showing	_	_	_	_
17-8	1822-1825	the	quantity[97]	new[97]	_	_
17-9	1826-1833	highest	quantity[97]	new[97]	_	_
17-10	1834-1836	EC	organization|quantity[97]	giv|new[97]	coref	17-50
17-11	1837-1843	yields	quantity[97]	new[97]	_	_
17-12	1844-1848	were	_	_	_	_
17-13	1849-1858	developed	_	_	_	_
17-14	1859-1861	by	_	_	_	_
17-15	1862-1871	culturing	_	_	_	_
17-16	1872-1873	a	object[98]	new[98]	_	_
17-17	1874-1883	monolayer	object[98]	new[98]	_	_
17-18	1884-1886	of	object[98]	new[98]	_	_
17-19	1887-1893	hiPSCs	object[98]|abstract[99]	new[98]|giv[99]	coref	17-47[0_99]
17-20	1894-1896	on	object[98]|abstract[99]	new[98]|giv[99]	_	_
17-21	1897-1898	a	object[98]|abstract[99]|object[101]	new[98]|giv[99]|new[101]	_	_
17-22	1899-1912	matrix-coated	object[98]|abstract[99]|object[101]	new[98]|giv[99]|new[101]	_	_
17-23	1913-1920	culture	object[98]|abstract[99]|abstract|object[101]	new[98]|giv[99]|giv|new[101]	_	_
17-24	1921-1926	plate	object[98]|abstract[99]|object[101]	new[98]|giv[99]|new[101]	_	_
17-25	1927-1930	and	_	_	_	_
17-26	1931-1933	by	_	_	_	_
17-27	1934-1942	treating	_	_	_	_
17-28	1943-1947	them	person[102]	giv[102]	coref	21-6[130_102]
17-29	1948-1952	with	person[102]	giv[102]	_	_
17-30	1953-1962	different	person[102]|substance[103]|abstract[104]	giv[102]|new[103]|new[104]	coref|coref|coref|coref	18-15[116_103]|22-4[149_104]|18-15[116_103]|22-4[149_104]
17-31	1963-1972	molecules	person[102]|substance[103]|abstract[104]	giv[102]|new[103]|new[104]	_	_
17-32	1973-1975	or	person[102]|abstract[104]	giv[102]|new[104]	_	_
17-33	1976-1982	growth	person[102]|abstract[104]|abstract[105]	giv[102]|new[104]|giv[105]	coref	24-13[0_105]
17-34	1983-1990	factors	person[102]|abstract[104]|abstract[105]	giv[102]|new[104]|giv[105]	_	_
17-35	1991-1993	in	person[102]|abstract[104]|abstract[105]	giv[102]|new[104]|giv[105]	_	_
17-36	1994-1995	a	person[102]|abstract[104]|abstract[105]|abstract[106]	giv[102]|new[104]|giv[105]|new[106]	_	_
17-37	1996-2001	timed	person[102]|abstract[104]|abstract[105]|abstract[106]	giv[102]|new[104]|giv[105]|new[106]	_	_
17-38	2002-2009	fashion	person[102]|abstract[104]|abstract[105]|abstract[106]	giv[102]|new[104]|giv[105]|new[106]	_	_
17-39	2010-2012	in	_	_	_	_
17-40	2013-2018	order	_	_	_	_
17-41	2019-2021	to	_	_	_	_
17-42	2022-2027	guide	_	_	_	_
17-43	2028-2031	the	event[107]	giv[107]	_	_
17-44	2032-2043	progressive	event[107]	giv[107]	_	_
17-45	2044-2059	differentiation	event[107]	giv[107]	_	_
17-46	2060-2062	of	event[107]	giv[107]	_	_
17-47	2063-2069	hiPSCs	event[107]|object	giv[107]|giv	coref	21-14
17-48	2070-2076	toward	_	_	_	_
17-49	2077-2080	the	abstract[110]	new[110]	_	_
17-50	2081-2083	EC	organization|abstract[110]	giv|new[110]	_	_
17-51	2084-2091	lineage	abstract[110]	new[110]	_	_
17-52	2092-2093	.	_	_	_	_

#Text=In this context , GSK3 inhibitors play an important role among the set of molecules necessary to induce the differentiation of pluripotent cells into mature ECs .
18-1	2094-2096	In	_	_	_	_
18-2	2097-2101	this	abstract[111]	new[111]	_	_
18-3	2102-2109	context	abstract[111]	new[111]	_	_
18-4	2110-2111	,	_	_	_	_
18-5	2112-2116	GSK3	abstract|abstract[113]	new|new[113]	coref|coref|coref|coref	20-12|21-10[132_113]|20-12|21-10[132_113]
18-6	2117-2127	inhibitors	abstract[113]	new[113]	_	_
18-7	2128-2132	play	_	_	_	_
18-8	2133-2135	an	abstract[114]	new[114]	_	_
18-9	2136-2145	important	abstract[114]	new[114]	_	_
18-10	2146-2150	role	abstract[114]	new[114]	_	_
18-11	2151-2156	among	abstract[114]	new[114]	_	_
18-12	2157-2160	the	abstract[114]|abstract[115]	new[114]|new[115]	_	_
18-13	2161-2164	set	abstract[114]|abstract[115]	new[114]|new[115]	_	_
18-14	2165-2167	of	abstract[114]|abstract[115]	new[114]|new[115]	_	_
18-15	2168-2177	molecules	abstract[114]|abstract[115]|substance[116]	new[114]|new[115]|giv[116]	_	_
18-16	2178-2187	necessary	abstract[114]|abstract[115]|substance[116]	new[114]|new[115]|giv[116]	_	_
18-17	2188-2190	to	abstract[114]|abstract[115]|substance[116]	new[114]|new[115]|giv[116]	_	_
18-18	2191-2197	induce	abstract[114]|abstract[115]|substance[116]	new[114]|new[115]|giv[116]	_	_
18-19	2198-2201	the	abstract[114]|abstract[115]|substance[116]|event[117]	new[114]|new[115]|giv[116]|new[117]	coref	23-11[0_117]
18-20	2202-2217	differentiation	abstract[114]|abstract[115]|substance[116]|event[117]	new[114]|new[115]|giv[116]|new[117]	_	_
18-21	2218-2220	of	abstract[114]|abstract[115]|substance[116]|event[117]	new[114]|new[115]|giv[116]|new[117]	_	_
18-22	2221-2232	pluripotent	abstract[114]|abstract[115]|substance[116]|event[117]|object[118]	new[114]|new[115]|giv[116]|new[117]|giv[118]	coref	24-10[162_118]
18-23	2233-2238	cells	abstract[114]|abstract[115]|substance[116]|event[117]|object[118]	new[114]|new[115]|giv[116]|new[117]|giv[118]	_	_
18-24	2239-2243	into	abstract[114]|abstract[115]|substance[116]|event[117]|object[118]	new[114]|new[115]|giv[116]|new[117]|giv[118]	_	_
18-25	2244-2250	mature	abstract[114]|abstract[115]|substance[116]|event[117]|object[118]|object[119]	new[114]|new[115]|giv[116]|new[117]|giv[118]|giv[119]	coref	21-16[0_119]
18-26	2251-2254	ECs	abstract[114]|abstract[115]|substance[116]|event[117]|object[118]|object[119]	new[114]|new[115]|giv[116]|new[117]|giv[118]|giv[119]	_	_
18-27	2255-2256	.	_	_	_	_

#Text=In particular , vascular progenitors derive during human development from latero-posterior mesoderm .
19-1	2257-2259	In	_	_	_	_
19-2	2260-2270	particular	_	_	_	_
19-3	2271-2272	,	_	_	_	_
19-4	2273-2281	vascular	abstract[120]	new[120]	_	_
19-5	2282-2293	progenitors	abstract[120]	new[120]	_	_
19-6	2294-2300	derive	_	_	_	_
19-7	2301-2307	during	_	_	_	_
19-8	2308-2313	human	abstract[121]	giv[121]	_	_
19-9	2314-2325	development	abstract[121]	giv[121]	_	_
19-10	2326-2330	from	abstract[121]	giv[121]	_	_
19-11	2331-2347	latero-posterior	abstract[121]|abstract|object[123]	giv[121]|new|new[123]	coref|coref	20-3[0_123]|20-3[0_123]
19-12	2348-2356	mesoderm	abstract[121]|object[123]	giv[121]|new[123]	_	_
19-13	2357-2358	.	_	_	_	_

#Text=To specify mesoderm , Wnt signaling , which is activated by GSK3 inhibition , is required .
20-1	2359-2361	To	_	_	_	_
20-2	2362-2369	specify	_	_	_	_
20-3	2370-2378	mesoderm	object	giv	coref	21-35
20-4	2379-2380	,	_	_	_	_
20-5	2381-2384	Wnt	abstract|abstract[126]	new|giv[126]	_	_
20-6	2385-2394	signaling	abstract[126]	giv[126]	_	_
20-7	2395-2396	,	_	_	_	_
20-8	2397-2402	which	_	_	_	_
20-9	2403-2405	is	_	_	_	_
20-10	2406-2415	activated	_	_	_	_
20-11	2416-2418	by	_	_	_	_
20-12	2419-2423	GSK3	abstract|abstract[128]	giv|new[128]	coref|coref	21-10|21-10
20-13	2424-2434	inhibition	abstract[128]	new[128]	_	_
20-14	2435-2436	,	_	_	_	_
20-15	2437-2439	is	_	_	_	_
20-16	2440-2448	required	_	_	_	_
20-17	2449-2450	.	_	_	_	_

#Text=In view of this , several authors have exploited GSK3 inhibitors to differentiate hiPSCs into ECs . Patsch et al. exposed a monolayer of hiPSC to GSK3 inhibitor CHIR-99021 ( CHIR ) and to mesoderm inducer bone morphogenetic protein 4 ( BMP4 ) .
21-1	2451-2453	In	_	_	_	_
21-2	2454-2458	view	abstract[129]	giv[129]	_	_
21-3	2459-2461	of	abstract[129]	giv[129]	_	_
21-4	2462-2466	this	abstract[129]	giv[129]	_	_
21-5	2467-2468	,	_	_	_	_
21-6	2469-2476	several	person[130]	giv[130]	_	_
21-7	2477-2484	authors	person[130]	giv[130]	_	_
21-8	2485-2489	have	_	_	_	_
21-9	2490-2499	exploited	_	_	_	_
21-10	2500-2504	GSK3	abstract|abstract[132]	giv|giv[132]	coref|coref	21-27|21-27
21-11	2505-2515	inhibitors	abstract[132]	giv[132]	_	_
21-12	2516-2518	to	_	_	_	_
21-13	2519-2532	differentiate	_	_	_	_
21-14	2533-2539	hiPSCs	abstract	giv	coref	27-20
21-15	2540-2544	into	_	_	_	_
21-16	2545-2548	ECs	object	giv	coref	22-12[151_0]
21-17	2549-2550	.	_	_	_	_
21-18	2551-2557	Patsch	person	new	_	_
21-19	2558-2560	et	_	_	_	_
21-20	2561-2564	al.	_	_	_	_
21-21	2565-2572	exposed	_	_	_	_
21-22	2573-2574	a	object[136]	new[136]	_	_
21-23	2575-2584	monolayer	object[136]	new[136]	_	_
21-24	2585-2587	of	object[136]	new[136]	_	_
21-25	2588-2593	hiPSC	object[136]|object	new[136]|new	_	_
21-26	2594-2596	to	_	_	_	_
21-27	2597-2601	GSK3	abstract|object[139]|object[140]	giv|new[139]|new[140]	appos|appos|appos	21-31[0_140]|21-31[0_140]|21-31[0_140]
21-28	2602-2611	inhibitor	object[139]|object[140]	new[139]|new[140]	_	_
21-29	2612-2622	CHIR-99021	object[140]	new[140]	_	_
21-30	2623-2624	(	_	_	_	_
21-31	2625-2629	CHIR	object	giv	_	_
21-32	2630-2631	)	_	_	_	_
21-33	2632-2635	and	_	_	_	_
21-34	2636-2638	to	_	_	_	_
21-35	2639-2647	mesoderm	object|object[144]|abstract[146]	giv|new[144]|new[146]	appos|appos|appos	21-42[0_146]|21-42[0_146]|21-42[0_146]
21-36	2648-2655	inducer	person|object[144]|abstract[146]	new|new[144]|new[146]	_	_
21-37	2656-2660	bone	object[144]|abstract[146]	new[144]|new[146]	_	_
21-38	2661-2674	morphogenetic	abstract|abstract[146]	new|new[146]	_	_
21-39	2675-2682	protein	abstract[146]	new[146]	_	_
21-40	2683-2684	4	abstract[146]	new[146]	_	_
21-41	2685-2686	(	_	_	_	_
21-42	2687-2691	BMP4	abstract	giv	coref	27-9
21-43	2692-2693	)	_	_	_	_
21-44	2694-2695	.	_	_	_	_

#Text=The combination of these two molecules led to the production of mature ECs in a relatively short time ( six days ) with 80 % efficiency .
22-1	2696-2699	The	abstract[148]	new[148]	_	_
22-2	2700-2711	combination	abstract[148]	new[148]	_	_
22-3	2712-2714	of	abstract[148]	new[148]	_	_
22-4	2715-2720	these	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
22-5	2721-2724	two	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
22-6	2725-2734	molecules	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
22-7	2735-2738	led	_	_	_	_
22-8	2739-2741	to	_	_	_	_
22-9	2742-2745	the	abstract[150]	giv[150]	_	_
22-10	2746-2756	production	abstract[150]	giv[150]	_	_
22-11	2757-2759	of	abstract[150]	giv[150]	_	_
22-12	2760-2766	mature	abstract[150]|object[151]	giv[150]|giv[151]	coref	25-21[172_151]
22-13	2767-2770	ECs	abstract[150]|object[151]	giv[150]|giv[151]	_	_
22-14	2771-2773	in	_	_	_	_
22-15	2774-2775	a	time[152]	new[152]	appos	22-20[153_152]
22-16	2776-2786	relatively	time[152]	new[152]	_	_
22-17	2787-2792	short	time[152]	new[152]	_	_
22-18	2793-2797	time	time[152]	new[152]	_	_
22-19	2798-2799	(	_	_	_	_
22-20	2800-2803	six	time[153]	giv[153]	_	_
22-21	2804-2808	days	time[153]	giv[153]	_	_
22-22	2809-2810	)	_	_	_	_
22-23	2811-2815	with	_	_	_	_
22-24	2816-2818	80	abstract[155]	giv[155]	_	_
22-25	2819-2820	%	quantity|abstract[155]	giv|giv[155]	_	_
22-26	2821-2831	efficiency	abstract[155]	giv[155]	_	_
22-27	2832-2833	.	_	_	_	_

#Text=However , mesoderm induction is only the first step of differentiation .
23-1	2834-2841	However	_	_	_	_
23-2	2842-2843	,	_	_	_	_
23-3	2844-2852	mesoderm	abstract[156]	giv[156]	coref	23-6[157_156]
23-4	2853-2862	induction	abstract[156]	giv[156]	_	_
23-5	2863-2865	is	_	_	_	_
23-6	2866-2870	only	abstract[157]	giv[157]	_	_
23-7	2871-2874	the	abstract[157]	giv[157]	_	_
23-8	2875-2880	first	abstract[157]	giv[157]	_	_
23-9	2881-2885	step	abstract[157]	giv[157]	_	_
23-10	2886-2888	of	abstract[157]	giv[157]	_	_
23-11	2889-2904	differentiation	abstract[157]|event	giv[157]|giv	coref	29-17
23-12	2905-2906	.	_	_	_	_

#Text=The second part starts upon mesodermal commitment by exposing the cells to factors that further induce the mature vascular phenotype .
24-1	2907-2910	The	abstract[159]	new[159]	_	_
24-2	2911-2917	second	abstract[159]	new[159]	_	_
24-3	2918-2922	part	abstract[159]	new[159]	_	_
24-4	2923-2929	starts	_	_	_	_
24-5	2930-2934	upon	_	_	_	_
24-6	2935-2945	mesodermal	object|event[161]	giv|new[161]	_	_
24-7	2946-2956	commitment	event[161]	new[161]	_	_
24-8	2957-2959	by	_	_	_	_
24-9	2960-2968	exposing	_	_	_	_
24-10	2969-2972	the	object[162]	giv[162]	coref	26-1[174_162]
24-11	2973-2978	cells	object[162]	giv[162]	_	_
24-12	2979-2981	to	_	_	_	_
24-13	2982-2989	factors	abstract	giv	_	_
24-14	2990-2994	that	_	_	_	_
24-15	2995-3002	further	_	_	_	_
24-16	3003-3009	induce	_	_	_	_
24-17	3010-3013	the	abstract[164]	new[164]	_	_
24-18	3014-3020	mature	abstract[164]	new[164]	_	_
24-19	3021-3029	vascular	abstract[164]	new[164]	_	_
24-20	3030-3039	phenotype	abstract[164]	new[164]	_	_
24-21	3040-3041	.	_	_	_	_

#Text=Gu set up a protocol through which , after 4 days of treatment with VEGF and bFGF , he produced mature ECs in only 8 days .
25-1	3042-3044	Gu	person	new	ana	25-19
25-2	3045-3048	set	_	_	_	_
25-3	3049-3051	up	_	_	_	_
25-4	3052-3053	a	abstract[166]	giv[166]	coref	27-11[180_166]
25-5	3054-3062	protocol	abstract[166]	giv[166]	_	_
25-6	3063-3070	through	_	_	_	_
25-7	3071-3076	which	_	_	_	_
25-8	3077-3078	,	_	_	_	_
25-9	3079-3084	after	_	_	_	_
25-10	3085-3086	4	time[167]	new[167]	_	_
25-11	3087-3091	days	time[167]	new[167]	_	_
25-12	3092-3094	of	time[167]	new[167]	_	_
25-13	3095-3104	treatment	time[167]|event	new[167]|new	_	_
25-14	3105-3109	with	time[167]	new[167]	_	_
25-15	3110-3114	VEGF	time[167]|substance	new[167]|new	coref	27-5
25-16	3115-3118	and	time[167]	new[167]	_	_
25-17	3119-3123	bFGF	time[167]|substance	new[167]|new	coref	27-7
25-18	3124-3125	,	_	_	_	_
25-19	3126-3128	he	person	giv	_	_
25-20	3129-3137	produced	_	_	_	_
25-21	3138-3144	mature	object[172]	giv[172]	coref	26-13[175_172]
25-22	3145-3148	ECs	object[172]	giv[172]	_	_
25-23	3149-3151	in	_	_	_	_
25-24	3152-3156	only	time[173]	new[173]	_	_
25-25	3157-3158	8	time[173]	new[173]	_	_
25-26	3159-3163	days	time[173]	new[173]	_	_
25-27	3164-3165	.	_	_	_	_

#Text=These cells , when tested , were molecularly and functionally similar to native ECs .
26-1	3166-3171	These	object[174]	giv[174]	coref	29-4[190_174]
26-2	3172-3177	cells	object[174]	giv[174]	_	_
26-3	3178-3179	,	_	_	_	_
26-4	3180-3184	when	_	_	_	_
26-5	3185-3191	tested	_	_	_	_
26-6	3192-3193	,	_	_	_	_
26-7	3194-3198	were	_	_	_	_
26-8	3199-3210	molecularly	_	_	_	_
26-9	3211-3214	and	_	_	_	_
26-10	3215-3227	functionally	_	_	_	_
26-11	3228-3235	similar	_	_	_	_
26-12	3236-3238	to	_	_	_	_
26-13	3239-3245	native	object[175]	giv[175]	coref	27-17[181_175]
26-14	3246-3249	ECs	object[175]	giv[175]	_	_
26-15	3250-3251	.	_	_	_	_

#Text=Paik et al. added VEGF , bFGF and BMP4 to an already established protocol to produce mature ECs from hiPSCs within 12 days .
27-1	3252-3256	Paik	person	new	_	_
27-2	3257-3259	et	_	_	_	_
27-3	3260-3263	al.	_	_	_	_
27-4	3264-3269	added	_	_	_	_
27-5	3270-3274	VEGF	substance	giv	_	_
27-6	3275-3276	,	_	_	_	_
27-7	3277-3281	bFGF	abstract	giv	_	_
27-8	3282-3285	and	_	_	_	_
27-9	3286-3290	BMP4	organization	giv	_	_
27-10	3291-3293	to	_	_	_	_
27-11	3294-3296	an	abstract[180]	giv[180]	coref	28-2[184_180]
27-12	3297-3304	already	abstract[180]	giv[180]	_	_
27-13	3305-3316	established	abstract[180]	giv[180]	_	_
27-14	3317-3325	protocol	abstract[180]	giv[180]	_	_
27-15	3326-3328	to	_	_	_	_
27-16	3329-3336	produce	_	_	_	_
27-17	3337-3343	mature	object[181]	giv[181]	_	_
27-18	3344-3347	ECs	object[181]	giv[181]	_	_
27-19	3348-3352	from	_	_	_	_
27-20	3353-3359	hiPSCs	object	giv	_	_
27-21	3360-3366	within	_	_	_	_
27-22	3367-3369	12	time[183]	new[183]	_	_
27-23	3370-3374	days	time[183]	new[183]	_	_
27-24	3375-3376	.	_	_	_	_

#Text=Although this protocol requires more time compared to other ones reported in literature , the aim of this study was different .
28-1	3377-3385	Although	_	_	_	_
28-2	3386-3390	this	abstract[184]	giv[184]	coref	30-6[197_184]
28-3	3391-3399	protocol	abstract[184]	giv[184]	_	_
28-4	3400-3408	requires	_	_	_	_
28-5	3409-3413	more	time[185]	new[185]	_	_
28-6	3414-3418	time	time[185]	new[185]	_	_
28-7	3419-3427	compared	_	_	_	_
28-8	3428-3430	to	_	_	_	_
28-9	3431-3436	other	object[186]	giv[186]	_	_
28-10	3437-3441	ones	object[186]	giv[186]	_	_
28-11	3442-3450	reported	_	_	_	_
28-12	3451-3453	in	_	_	_	_
28-13	3454-3464	literature	abstract	new	_	_
28-14	3465-3466	,	_	_	_	_
28-15	3467-3470	the	abstract[188]	new[188]	_	_
28-16	3471-3474	aim	abstract[188]	new[188]	_	_
28-17	3475-3477	of	abstract[188]	new[188]	_	_
28-18	3478-3482	this	abstract[188]|event[189]	new[188]|new[189]	_	_
28-19	3483-3488	study	abstract[188]|event[189]	new[188]|new[189]	_	_
28-20	3489-3492	was	_	_	_	_
28-21	3493-3502	different	_	_	_	_
28-22	3503-3504	.	_	_	_	_

#Text=In fact , these cells were used to draw an RNA signature at different stage of differentiation .
29-1	3505-3507	In	_	_	_	_
29-2	3508-3512	fact	_	_	_	_
29-3	3513-3514	,	_	_	_	_
29-4	3515-3520	these	object[190]	giv[190]	coref	30-13[199_190]
29-5	3521-3526	cells	object[190]	giv[190]	_	_
29-6	3527-3531	were	_	_	_	_
29-7	3532-3536	used	_	_	_	_
29-8	3537-3539	to	_	_	_	_
29-9	3540-3544	draw	_	_	_	_
29-10	3545-3547	an	abstract[192]	new[192]	_	_
29-11	3548-3551	RNA	organization|abstract[192]	new|new[192]	_	_
29-12	3552-3561	signature	abstract[192]	new[192]	_	_
29-13	3562-3564	at	_	_	_	_
29-14	3565-3574	different	abstract[193]	new[193]	_	_
29-15	3575-3580	stage	abstract[193]	new[193]	_	_
29-16	3581-3583	of	abstract[193]	new[193]	_	_
29-17	3584-3599	differentiation	abstract[193]|event	new[193]|giv	coref	30-7
29-18	3600-3601	.	_	_	_	_

#Text=The last step included in the differentiation protocol is the purification of positive cells .
30-1	3602-3605	The	abstract[195]	new[195]	coref	30-10[198_195]
30-2	3606-3610	last	abstract[195]	new[195]	_	_
30-3	3611-3615	step	abstract[195]	new[195]	_	_
30-4	3616-3624	included	_	_	_	_
30-5	3625-3627	in	_	_	_	_
30-6	3628-3631	the	abstract[197]	giv[197]	_	_
30-7	3632-3647	differentiation	event|abstract[197]	giv|giv[197]	_	_
30-8	3648-3656	protocol	abstract[197]	giv[197]	_	_
30-9	3657-3659	is	_	_	_	_
30-10	3660-3663	the	abstract[198]	giv[198]	coref	31-1[200_198]
30-11	3664-3676	purification	abstract[198]	giv[198]	_	_
30-12	3677-3679	of	abstract[198]	giv[198]	_	_
30-13	3680-3688	positive	abstract[198]|object[199]	giv[198]|giv[199]	coref	31-12[0_199]
30-14	3689-3694	cells	abstract[198]|object[199]	giv[198]|giv[199]	_	_
30-15	3695-3696	.	_	_	_	_

#Text=This step is essential to fish out a homogenous subset of cells and to ensure the safety needed for the future cell implantation and engraftment .
31-1	3697-3701	This	abstract[200]	giv[200]	_	_
31-2	3702-3706	step	abstract[200]	giv[200]	_	_
31-3	3707-3709	is	_	_	_	_
31-4	3710-3719	essential	_	_	_	_
31-5	3720-3722	to	_	_	_	_
31-6	3723-3727	fish	_	_	_	_
31-7	3728-3731	out	_	_	_	_
31-8	3732-3733	a	abstract[201]	new[201]	_	_
31-9	3734-3744	homogenous	abstract[201]	new[201]	_	_
31-10	3745-3751	subset	abstract[201]	new[201]	_	_
31-11	3752-3754	of	abstract[201]	new[201]	_	_
31-12	3755-3760	cells	abstract[201]|object	new[201]|giv	_	_
31-13	3761-3764	and	_	_	_	_
31-14	3765-3767	to	_	_	_	_
31-15	3768-3774	ensure	_	_	_	_
31-16	3775-3778	the	abstract[203]	new[203]	_	_
31-17	3779-3785	safety	abstract[203]	new[203]	_	_
31-18	3786-3792	needed	_	_	_	_
31-19	3793-3796	for	_	_	_	_
31-20	3797-3800	the	event[205]	new[205]	_	_
31-21	3801-3807	future	event[205]	new[205]	_	_
31-22	3808-3812	cell	place|event[205]	giv|new[205]	_	_
31-23	3813-3825	implantation	event[205]	new[205]	_	_
31-24	3826-3829	and	_	_	_	_
31-25	3830-3841	engraftment	event	new	_	_
31-26	3842-3843	.	_	_	_	_

#Text=Cell sorting is usually performed by using magnetic beads on which surface specific antibodies are adsorbed .
32-1	3844-3848	Cell	person|abstract[208]	new|new[208]	_	_
32-2	3849-3856	sorting	abstract[208]	new[208]	_	_
32-3	3857-3859	is	_	_	_	_
32-4	3860-3867	usually	_	_	_	_
32-5	3868-3877	performed	_	_	_	_
32-6	3878-3880	by	_	_	_	_
32-7	3881-3886	using	_	_	_	_
32-8	3887-3895	magnetic	object[209]	new[209]	_	_
32-9	3896-3901	beads	object[209]	new[209]	_	_
32-10	3902-3904	on	_	_	_	_
32-11	3905-3910	which	_	_	_	_
32-12	3911-3918	surface	place|substance[211]	new|new[211]	coref|coref	33-1[212_211]|33-1[212_211]
32-13	3919-3927	specific	substance[211]	new[211]	_	_
32-14	3928-3938	antibodies	substance[211]	new[211]	_	_
32-15	3939-3942	are	_	_	_	_
32-16	3943-3951	adsorbed	_	_	_	_
32-17	3952-3953	.	_	_	_	_

#Text=These antibodies are directed against mature endothelial markers such as CD31 or VE-cadherin ( also known as CD144 ) .
33-1	3954-3959	These	substance[212]	giv[212]	_	_
33-2	3960-3970	antibodies	substance[212]	giv[212]	_	_
33-3	3971-3974	are	_	_	_	_
33-4	3975-3983	directed	_	_	_	_
33-5	3984-3991	against	_	_	_	_
33-6	3992-3998	mature	abstract[214]	new[214]	_	_
33-7	3999-4010	endothelial	place|abstract[214]	new|new[214]	_	_
33-8	4011-4018	markers	abstract[214]	new[214]	_	_
33-9	4019-4023	such	abstract[214]	new[214]	_	_
33-10	4024-4026	as	abstract[214]	new[214]	_	_
33-11	4027-4031	CD31	abstract[214]|abstract	new[214]|new	_	_
33-12	4032-4034	or	abstract[214]	new[214]	_	_
33-13	4035-4046	VE-cadherin	abstract[214]|object	new[214]|new	_	_
33-14	4047-4048	(	_	_	_	_
33-15	4049-4053	also	_	_	_	_
33-16	4054-4059	known	_	_	_	_
33-17	4060-4062	as	_	_	_	_
33-18	4063-4068	CD144	_	_	_	_
33-19	4069-4070	)	_	_	_	_
33-20	4071-4072	.	_	_	_	_
